ClinicalTrials.gg
Enrolling by invitationNCT06264609Updated Apr 1, 2026

Precision Medicine Approach for Osteoporosis - Follow Up Study

A Phase 4 interventional study of Alendronate and Teriparatide in Osteoporosis, sponsored by Paul F Netzel. Enrolling by invitation at 1 site in United States. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Paul F Netzel · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
45 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies testing alendronate in Osteoporosis — 2 open to participants now, 4 under way, none of them phase 3. Alendronate · Osteoporosis.

Planned enrollment
36th of 51
40 · median 60
Started
2024
the only one that year
Phase 4
17 of 51
2 open now
Registered
50th of 51
by date

Among the 51 studies testing alendronate in Osteoporosis, this one is the 36th largest by planned enrollment, is the only one that started in 2024, is one of 17 in phase 4, and was the 50th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

2 of the 51 studies testing alendronate in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alendronate

Alendronate: first FDA approval 1995 (FOSAMAX), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 45 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing alendronate in Osteoporosis, or all of them as a file.
02

Study summary

Osteoporosis is a health problem of major proportions. It affects more than 40 million Americans and results in more than 2 million fractures annually among Medicare patients alone. Hospital admissions for osteoporotic fractures exceed those of heart attacks, strokes and breast cancer combined. Osteoporosis is commonly considered a disease associated with menopause. This estrogen deficiency related bone loss is characterized by high bone turnover with increased resorption without commensurate changes in bone formation. It is in contrast to age-related bone loss, which starts as early as in the fourth decade of life and continues with increasing age. Age-related bone loss is usually associated with lower bone turnover and decreased bone formation is the main abnormality.

Current therapies do not address age-related bone loss and the special needs of the age-related osteoporosis population is currently ignored. This is to a great degree due to difficulties associated with the bone biopsy necessary for unequivocal determination of bone turnover status. Thus, the current standard of care relies on starting with an antiresorber, which is of limited effectiveness in age-related osteoporosis, and in fact impedes the effectiveness of the appropriate anabolic medication. In a current ongoing study - Novel precision medicine approach to treatment of osteoporosis based on bone turnover. EIRB#70781; efforts are focused on addressing this particular problem.

Our follow-up study seeks to achieve one specific aim: to compare effectiveness of Alendronate vs Teriparatide after participants have been switched at the end of treatment at year one, to the other drug at year two for the same duration of treatment.

Read the detailed description

This will be a prospective, longitudinal crossover trial for participants who have completed therapy in the main trial - Novel precision medicine approach to treatment of osteoporosis based on bone turnover. EIRB#70781.

Participants will be informed of the continuation / follow-up study at enrollment into the main trial. Participants will be approached for further participation in the continuation trial near the end of the initial 12 months treatment period. Consent will be obtained at the final visit of the main trial and crossover therapy will be initiated at that time.

Participants in Group 1 low turnover, who have received Teriparatide in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Alendronate for 12 months. Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Teriparatide for 12 months. Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant responded to therapy; will be continued on Alendronate for 12 months.

03

Conditions studied

  • Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed Osteoporosis by DXA (BMD t-score = -2.5 with or without fragility fractures)
  2. Prior enrollment and completion of therapy in the "Novel precision medicine approach to treatment of osteoporosis based on bone turnover" trial.3) Premenopausal, menopausal, and females.
  3. 45 years old and older.
  4. Normal levels of Vitamin D
  5. Absence of all exclusion criteria on clinical workup. Patients diagnosed as osteoporotic due to the presence of

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or trying to become pregnant or are breastfeeding
  2. Use of systemic anticoagulation (blood thinner)
  3. Planned or anticipated oral surgery within the next 12 months
  4. Planning to move out of the area within 18 months of the study
  5. Inability to stand or sit upright for at least 30 minutes
  6. Chronic alcoholism and/or drug addiction
  7. Prior radiation therapy (external beam or implant radiation) involving the skeleton (only if randomized to the bone forming drug (anabolic Forteo®))
  8. Systemic illnesses or organ diseases that may affect bone (except type 1 or type 2 diabetes mellitus)
  9. Clinical condition that may limit study participation (e.g., heart diseases (unstable angina), lung diseases (severe ), other infections)
  10. Abnormalities of the esophagus (tube connecting the mouth to the stomach) which delay esophageal emptying such as stricture (narrowing) or achalasia (a condition that prevents normal swallowing)
  11. Have other bone diseases that are not linked to age or menopause
  12. Have a history of (cancer), not including non-melanoma skin cancer.
  13. Vitamin D (Calcidiol) level below the normal range (below 20ng/mL).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Group 1 Low Turnover - crossover

    Alendronate

    Drug: Alendronate

  • Experimental
    Group 2 Low Turnover - crossover

    Teriparatide

    Drug: Teriparatide

  • Experimental
    Group 2 Low Turnover - continuation

    Alendronate

    Drug: Alendronate

Interventions

  • Participants in Group 1 low turnover, who have received Teriparatide in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Alendronate for 12 months.

    Also known as: Grp 1

  • Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Teriparatide for 12 months.

    Also known as: Grp 2

  • Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant responded to therapy; will be continue on Alendronate for 12 months.

    Also known as: Grp 2c

06

What researchers measure

Primary outcomes

  1. Percent change in bone loss

    The primary endpoint for the follow up study will be bone loss as determined by the percent change in DXA absolute values of the lumbar spine, femoral neck, total hip and radius measured at baseline, at the end of the one-year trial; and at end of the one year follow up study. DXA is chosen because of its wide availability, low radioactivity exposure, and clinical use.

    Time frame: 12 months

Secondary outcomes

  1. Percent change in Bone Mass Density at the hip

    Secondary endpoints will be percent change in BMD at the hip measured at baseline, at the end of the one-year trial; and at end of the one year follow up study. DXA is chosen because of its wide availability, low radioactivity exposure, and clinical use.

    Time frame: 12 months

Other outcomes

  1. Trabecular bone score (TBS)

    A measure of trabecular texture derived from lumbar spine DXA images measure of trabecular texture derived from lumbar spine DXA images which predicts fracture independently of BMD. TBS is calculated as the slope of the log-log transform of the 2D variogram, where the slope characterizes the rate of gray-level amplitude variations. A steep variogram slope with a high TBS value is associated with better bone structure, whereas low TBS values indicate worse bone structure.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2029, 70 months after the start.

Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's planned 70 months is above that.

Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2024
First posted
Feb 20, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06264609
Lead sponsor
Paul F Netzel
Responsible party
Paul F Netzel (Principal Investigator, University of Kentucky) — Sponsor-investigator
First posted
Feb 20, 2024
Start date
Feb 1, 2024
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Apr 1, 2026

Study contacts

Paul Netzel, DNP
principal investigator · University of Kentucky

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alendronate · Teriparatide

Start the discussion